Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
1,700.00
+13.80 (0.82%)
May 13, 2025, 3:29 PM IST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
India Formulations | 164.18B |
Log In |
Log In |
Log In |
Log In |
India Formulations Growth | 12.87% |
Log In |
Log In |
Log In |
Log In |
US Formulations | 161.74B |
Log In |
Log In |
Log In |
Log In |
US Formulations Growth | 8.34% |
Log In |
Log In |
Log In |
Log In |
Total Formulations | 488.44B |
Log In |
Log In |
Log In |
Log In |
Total Formulations Growth | 9.67% |
Log In |
Log In |
Log In |
Log In |
Active Pharmaceutical Ingredients (API) | 20.12B |
Log In |
Log In |
Log In |
Log In |
Active Pharmaceutical Ingredients (API) Growth | 6.56% |
Log In |
Log In |
Log In |
Log In |
Others Segment | 1.83B |
Log In |
Log In |
Log In |
Log In |
Others Segment Growth | -25.38% |
Log In |
Log In |
Log In |
Log In |
Emerging Market | 91.95B |
Log In |
Log In |
Log In |
Log In |
Emerging Market Growth | 9.39% |
Log In |
Log In |
Log In |
Log In |
Rest of the World Formulations | 70.58B |
Log In |
Log In |
Log In |
Log In |
Rest of the World Formulations Growth | 6.00% |
Log In |
Log In |
Log In |
Log In |
Other Operating | 5.64B |
Log In |
Log In |
Log In |
Log In |
Other Operating Growth | -27.19% |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Sales per Medical Representative |
Log In |
Log In |
Log In |
Log In |
Sales per Medical Representative Growth |
Log In |
Log In |
Log In |
Log In |
Number of Medical Representatives |
Log In |
Log In |
Log In |
Log In |
Number of Medical Representatives Growth |
Log In |
Log In |
Log In |
Log In |